title: [AUO-study AB34/09: an open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy of locally advanced/metastatic urothelial carcinoma in patients with wild-type HRAS - PURO].
authors.affiliation: Geschäftsstelle der AUO, MeckEvidence, Seestraße 11, 17252 Schwarz, Deutschland. AUO@MeckEvidence.de
authors.forename: H
authors.initials: H
authors.lastname: Rexer
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D000077544:Panitumumab; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D003841:Deoxycytidine; D000077544:Panitumumab; D002945:Cisplatin; D000093542:Gemcitabine